Can testicular cancer be cured?

Yes. The National Cancer Institute states that "most testicular cancers can be cured, even if diagnosed at an advanced stage." That is unusual. Very few cancers stay curable once they spread. This one does.

The numbers back it up. NCI's summary for doctors reports that for seminomas, all stages counted together, "the cure rate exceeds 90%." For low-stage seminomas or nonseminomas, "the cure rate approaches 100%." SEER, the federal cancer surveillance program, puts five-year relative survival near 97 percent. Alongside that it publishes 9,810 new cases and 630 deaths for 2026 in the United States — a projection produced by the American Cancer Society rather than a SEER count. Half of those cases are in men aged 20 to 34. The median age at diagnosis is 33.

Why this cancer responds so well

Testicular cancer nearly always starts in germ cells, the cells that make sperm. Germ cell tumors divide fast. They also repair damaged DNA poorly. That pairing leaves them wide open to platinum chemotherapy. Since the mid-1980s the standard mix has been BEP. The letters stand for bleomycin, etoposide, and cisplatin. It replaced an older combination and pushed cure rates higher still.

Doctors also have something rare here. Blood tests track the tumor in real time. Three markers are followed. The first is alpha-fetoprotein, or AFP. It is raised in 40 to 60 percent of men with nonseminomas. NCI notes that "seminomas do not produce AFP." So a raised AFP rules out pure seminoma. The second is beta-hCG. It is raised in about 14 percent of stage I pure seminomas before surgery, and in roughly half of seminomas that have spread. The third is lactate dehydrogenase, or LDH. It adds useful information in advanced disease. All three feed the S part of the staging system. S0 means normal levels, and S3 means very high ones. Falling markers during chemotherapy are an early sign the drugs are working.

Treatment usually opens with surgery to remove the testicle through a cut in the groin. Doctors call this an inguinal orchiectomy. That one operation both makes the diagnosis and treats the main tumor.

The catch worth knowing

A clean scan after surgery does not close the case. NCI reports that "nearly 20% of patients with seminoma and 30% of patients with nonseminoma who have normal CT scans and serum tumor markers will subsequently relapse if not given additional treatment after orchiectomy."

So active surveillance is not casual waiting. It means scans and marker blood tests on a fixed schedule for years. Relapses caught on that schedule are usually still curable. Ones found late, because visits were skipped, often are not. Keeping every follow-up appointment is the most useful thing a patient can do.

Three things drive the outlook. One is whether the tumor is seminoma or nonseminoma. One is how far it has spread. One is how high the markers run. For men with distant spread or bulky lymph nodes in the belly, teams use a scale from the International Germ Cell Cancer Consensus Group. It sorts patients into good, intermediate, and poor risk groups. That grouping sets how much chemotherapy is given.

Before treatment, and long after

Ask about sperm banking before chemotherapy or radiation starts. Afterward is too late. Fertility often returns, and NCI notes that about 70 percent of men can father children after treatment. But that is not everyone, and banking only works beforehand.

A cure also brings a long tail. Survivors carry a raised risk of second cancers. They carry a raised risk of heart and blood vessel disease decades later too. So long-term checkups with a primary care doctor matter as much as the cancer visits did.